These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 31406978)

  • 21. Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D
    Ferraiolo M; Ponthot R; Atik H; Koener B; Hanson J; Hermans E
    Fundam Clin Pharmacol; 2022 Dec; 36(6):976-984. PubMed ID: 35767599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
    Tuplin EW; Holahan MR
    Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.
    Aftab A; Gao K
    Expert Opin Drug Discov; 2017 Oct; 12(10):1067-1081. PubMed ID: 28718334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective.
    Watanabe Y; Yamada S; Otsubo T; Kikuchi T
    Drug Des Devel Ther; 2020; 14():5559-5574. PubMed ID: 33376301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
    Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
    Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
    [No Abstract]   [Full Text] [Related]  

  • 31. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
    Simon N; Azorin JM
    Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cariprazine: First Global Approval.
    McCormack PL
    Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
    Stummer L; Markovic M; Maroney M
    Neurodegener Dis Manag; 2020 Aug; 10(4):205-217. PubMed ID: 32618483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.
    Baumann P; Bauknecht P; Kuzin M; Schoretsanitis G
    Int J Psychiatry Clin Pract; 2023 Nov; 27(4):367-384. PubMed ID: 37428441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
    Mailman RB; Murthy V
    Curr Pharm Des; 2010; 16(5):488-501. PubMed ID: 19909227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm.
    Citrome L
    J Clin Psychopharmacol; 2017 Apr; 37(2):138-147. PubMed ID: 28141623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.